European giant Novo Nordisk vowed to lower prices for its popular weight-loss drug to reach more U.S. customers.

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

This potential loss of strength when taking Ozempic could be a particular concern for adults over the age of 60 who are at a higher risk of muscle loss and reduced mobility.

It’s the most high-profile example yet of a controversial industry practice called preferred pharmacy networks, or PPNs ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

When people were randomised to receive either a placebo or Ozempic, they became biologically younger with the latter drug ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

GLP-1 drugs often cause weight loss because they mimic the GLP-1 hormone the body naturally produces after eating. Appetite ...